Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

Related news

Bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B

GSKGSK plc2026-06-25 13:46 EST

GSK to showcase long-term outcomes and pipeline expansion with latest oncology research at ASCO and EHA

GSKGSK plc2026-06-25 13:46 EST

GSK’s RSV vaccine, Arexvy, receives expanded approval in Japan for adults aged 18–59 at increased risk

GSKGSK plc2026-06-25 13:46 EST

GSK enters exclusive collaboration with SBP Group, a market leader in hepatology in China, to accelerate bepirovirsen at launch

GSKGSK plc2026-06-25 13:46 EST

GSK and Xenoport resubmit new drug application for Solzira™ in restless legs syndrome

GSKGSK plc2026-06-25 13:46 EST

GlaxoSmithKline receives European Commission approval to market alli® (orlistat 60mg)

GSKGSK plc2026-06-25 13:46 EST

GSK’s paediatric pneumococcal candidate vaccine Synflorix™ receives positive opinion in Europe

View all latest news

GSK plc

GSK plc is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

GSKGSK plc2026-06-26 04:56 EST

GSK announces commencement of tender offer to acquire Nuvalent, Inc.

GSKGSK plc2026-06-26 04:56 EST

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

GSKGSK plc2026-06-26 04:56 EST

GSK’s momelotinib granted Orphan Drug Designations in the US and EU for VEXAS syndrome

GSKGSK plc2026-06-26 04:56 EST

GSK enters agreement to acquire Nuvalent, Inc.

GSKGSK plc2026-06-26 04:56 EST

Bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B

Stock data

Close: —
Market cap: —
Exchange: NYSE
Sector: Biotechnology
Location: United States